| Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous ... - PR Newswire (press release) |
|
|
PR Newswire (press release) Vascugel has demonstrated clinical proof of concept in two Phase 2 clinical trials involving patients with ESRD who require a permanent arteriovenous (AV) |